Home DiscGenics Inc.

DiscGenics Inc.

Clinical Study of Cell Therapy for Disc Degeneration Clears Final Planned Safety Review

The DSMC completed a third and final planned mid-trial safety review following treatment of the first six subjects in the high dose study cohort, each of whom was treated based on random assignment into one of three arms: high dose IDCT study treatment, vehicle or placebo.